Proteinuria Therapeutics Market
What is proteinuria? Proteinuria is high levels of protein in your urine. This condition may also be an indication of kidney damage caused by high levels of acidity in the blood. Smaller proteins are filtered by the glomerulus, but sometimes not enough larger proteins, usually amino acids, escape to the urine causing proteinuria.
Most people with chronic kidney disease may suffer from proteinuria. Proteinuria can cause some uncomfortable side effects like cramps in the lower abdomen, constipation, nausea, diarrhea, dizziness, and gas. Some of the more severe side effects such as hyperlipidemia, edema, hypertension, tingling, numbness, and liver disease, may occur in certain cases of proteinuria. If proteinuria is present, it is very important to manage it.
Major players operating in the global proteinuria therapeutics market are focused on R&D to expand their product portfolio. For instance, on June 06, 2021, Novartis AG announced Phase II primary endpoint data that demonstrated investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reducing protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure. It was also effective in stabilizing kidney function in patients with IgA nephropathy.
Major players operating in the global proteinuria therapeutics market are also focused on approval and launch of new drugs to expand their product portfolio. For instance, in May 2021, GlaxoSmithKline plc. received the European Commission approval for the expanded use of intravenous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis, which can lead to proteinuria, in Europe.
Ask for PDF sample copy of the Proteinuria Therapeutics market report @ https://www.coherentmarketinsights.com/insight/request-pdf/4491
Global Proteinuria Therapeutics Market: Drivers
High prevalence of kidney diseases is expected to propel growth of the global proteinuria therapeutics market over the forecast period. For instance, according to the study, ‘Risk Factors and Rate of Progression of CKD in Children’, published in June 2019 in Kidney International Reports, 38% children experienced progression of chronic kidney disease within 2 years of follow-up.
Moreover, increasing geriatric population is also expected to aid in growth of the global proteinuria therapeutics market. For instance, according to the United Nations, Department of Economic and Social Affairs, Population Division, the geriatric population in China is expected to reach 246,986 thousands in 2030 from 164,487 thousands in 2019.
Major players operating in the global proteinuria therapeutics market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Chinook Therapeutics Inc., a biotechnology firm, partnered with AbbVie, for worldwide exclusive rights to ‘atrasentan’, an endothelin receptor antagonist used for the treatment of primary glomerular diseases, which are characterized by proteinuria.
Major players operating in the global proteinuria therapeutics market are also focused on R&D to expand their product portfolio. For instance, in March 2021, Calliditas Therapeutics AB submitted a New Drug Application to the U.S. Food and Drug Administration for Nefecon, a novel oral formulation used for the treatment of primary IgA Nephropathy.
Global Proteinuria Therapeutics Market – Competitive landscape
Major players operating in the global proteinuria therapeutics market include, AbbVie Inc., Calliditas Therapeutics AB, Chinook Therapeutics Inc., GlaxoSmithKline plc, Ligand Pharmaceuticals Inc., Novartis International AG, Retrophin, Inc., Travere Therapeutics Inc., and Walden Biosciences.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/4491
Global Proteinuria Therapeutics Market–Taxonomy
By Drug Class:
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Antagonists (ARBs)
By Route of Administration:
By Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Got any Query? Feel free to ask us at: https://www.coherentmarketinsights.com/insight/talk-to-analyst/4491
Table of Content
Global Proteinuria Therapeutics Market Research Report
Section 1: Global Proteinuria Therapeutics Industry Overview
Section 2: Global Economic Impact on Proteinuria Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Proteinuria Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Proteinuria Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027